

Research Article

A novel approach for spectrophotometric determination of naproxen

DR. HANA SH. MAHMOOD^{1*}, THURA Z. FATIH-ALLA²¹Assit. prof. in analytical Chemistry, Department of chemistry, College of Science, University of Mosul, Mosul-Iraq²Lect. in analytical Chemistry, Department of pharmacy, Alnoor University College, Ninawa-Iraq

*Corresponding Author

Email ID: hnsheker@yahoo.com, thura.ziyad@gmail.com

Received: 10.07.20, Revised: 09.08.20, Accepted: 08.09.20

ABSTRACT

In the present pandemic, Naproxen is one of the important drugs in which it blocks the binding groove of RNA nucleoprotein of influenza virus, in this paper (S)-2-(6-methoxynaphthalen-2-yl)-(+)-propionic acid (Naproxen) has been refluxed with hydrobromic acid and acetic acid to form (S)-2-(6-hydroxynaphthalen-2-yl)-(+)-propionic acid (the hydroxyl analog of Naproxen, HAN). HAN has been oxidized with iron (III) ion followed by complex-formation reaction with 2,2-bipyridyl at 35°C in acidic medium to form an orange-red, complex that is soluble in water with good stability and exhibits maximum absorption at 523 nm. Concentration linearity range was from 0.25 to 10 µg/ml of HAN. The calculated molar absorptivity is 6.0×10^4 l/mol.cm, Sandell's index for sensitivity is 0.0260 µg/cm², relative error % is from -0.1 to 0.15, and the range of relative standard deviation % is from ± 0.10 to ± 0.35 % depending on the concentration level. 0.0132 µg/ml is the limit of detection (LOD) and 0.0442 µg/ml is the limit of quantitation (LOQ). Nap has been determined in pure form. The application to the Naproxen Tablets requires an extraction by ethyl acetate in acidic medium.

Keywords: Naproxen, influenza, spectrophotometric, reflux, 2,2-bipyridyl, extraction

INTRODUCTION

Naproxen (Nap) [1] and Nap analogues exhibit broad antiviral activity against influenza [2]. The novel properties of antiviral structure of Nap against the nucleoprotein of influenza A virus has been discovered from 2013 [3], followed by the evaluation of the antiviral properties of Nap against SARS-CoV-2 and show that Nap binding to the nucleoprotein of SARS-CoV2 inhibits viral replication and protected the bronchial epithelia against SARS-CoV-2 induced damage [4].

Nap is already an analgesic, anti-inflammatory drug with antipyretic activities and commonly used in the treatment of acute gout, dysmenorrhea and arthritis [5], chemically, it acts as a weak acid with a pK_a value of 4.2 classified as a low-solubility high-permeability drug [6].

My first manuscript for the determination of Nap in tablet include a coupling with the diazotized p-aminobenzoic acid in alkaline medium after a modification to the hydroxy analog to produce an orange azo dye measured at 500 nm. Beer's law was then followed over the range from 0.5 to 32.5 µg/ml, this coloring method require many analytical reagents with many addition steps [7]. In the later manuscript Potassium permanganate was used for oxidation of the synthesized hydroxy analog of Nap by two procedures, in the first, the oxidation has occurred in acidic medium, the excess of permanganate was followed at 545 nm

as a decrease with the increase in the modulate Nap. Beer's law is followed from 1 to 8 µg/ml. In the second, potassium permanganate was used to oxidize the hydroxy analog of Nap in basic medium; the manganate produced was followed at 610 nm. The linearity range is followed from 2 to 7 µg/ml [8].

Other reported methods for quantitative determination of Nap include electrochemical method [9], Ion selective electrode [10], chemiluminescence [11], Conductometric [12], and chromatographic methods; HPLC-uv detection [13 - 16], LC-MS [17].

The large hydrophobic aromatic region present in the Nap molecule disfavors interactions with water molecules [18], hydrogen-bonding possibilities via the COOH group have been used for crystal structure of Nap by the interaction with π-stacking from the aromatic region nicotinamide and isonicotinamide [19], picolinamide [20], bipyridine and piperazine [21].

A spectrophotometric assay of Nap at uv region was reported by Sloka, et al [22], Nijhu, et al [23], Maheshwari, et al [24] and Jain, et al [25].

The correlation of molecular structure with observed physicochemical properties is a fundamental activity in the chemical sciences [26]. The problem in this drug is its chemically inert structure toward development reagents, in this

work Nap is converted into a chemically active compound by modification to hydroxyl analog, then develop a color reaction by an oxidation (with ferric ion)– the reduced iron undergoes a complex formation reaction with 2,2'-bipyridyl reagent.

EXPERIMENTAL

Apparatus

BEL balance was used for weight measurements, reflux was utilized by electrothermal heater and stirring was utilized by Wisd stirrer and water bath type KARL KOLB Scientific Technical Supplies, West Germany. pH measurements were performed using HANNA 301 pH meter, 1.0 cm quartz cells and double-beam Jasco V-630 spectrophotometer were used.

Reagents

Analytical grade chemicals were used.

-Hydroxy analog of Naproxen (HAN) (100 µg / ml): dissolve 0.0100 g of HAN in 2 ml ethanol, then dilute to the make of 100 ml volumetric flask. Keep the solution into a dark bottle to gate stable solution for at least one month.

-Ferric Chloride (FeCl₃) (5x10⁻³): dissolve 0.0811g of FeCl₃ in 5 ml acetic acid (1 M) and dilute to 100 ml.

-2,2'-Bipyridyl (1x10⁻² M): dissolve 0.1561 g in 4 ml ethanol and dilute to 100 ml.

-Pharmaceutical preparation (Naproxen Tablet(500 mg)): 10 tablets of Nap was grinded to a fine particles and a weight equivalent to one tablet ,was dissolved in 3 ml ethyl acetate and 1 ml HCl(3M), two layer was separated , the organic layer was transferred to another tube and extraction was repeated 3 times , 1 ml of saturated solution of NaCl was added to organic layer and sufficient amount of sodium sulphate was added after separation, The layer was left on air for drying [27].

The pure dried extract of Naproxen was modified to the hydroxyl analog which produce pink solid crystals with melting point of 190-191°C.

Chemical reactions

1-Modification reaction of Naproxen: This step involves a conversion of Nap into a hydroxy analog (HAN) using hydrobromic acid in presence of acetic acid at a certain amount.




Fig.1: Modification reaction of Naproxen to the hydroxy analog

Modification reaction of Naproxen-Formation of HAN: 0.04 mol of pure Naproxen (9.2 g) was mixed with 25 ml hydrobromic acid (48%) and 25 ml acetic acid, the mixture was refluxed for 1.5

hour and then was cooled, diluted with 25 ml distilled water, filtrated, dried and finally was recrystallized using ethanol [28].

2- Oxidation of HAN by ferric chloride.




Fig.2: Oxidation reaction of HAN

Complex-formation reaction between ferrous chloride and 2,2'-bipyridyl




Fig.3: Complex-formation reaction between ferrous with 2,2'-bipyridyl

Study of the optimum reaction conditions
Selection of acid and its amount

Effect of different amount of many acids on absorption intensity has been studied (Table1).

Table 1: Selection of acid and its amount.

| Acid used (1M) | Absorbance/ ml of acid | | | | | |
|--------------------------------|------------------------|--------|--------|--------|--------|--------|
| | 0 | 0.25 | 0.5 | 1.0 | 1.5 | 2.0 |
| CH ₃ COOH | 0.330 at pH= 3.61 | 0.281 | 0.262 | 0.195 | 0.137 | 0.108 |
| pH | | 3.35 | 3.14 | 3.04 | 2.98 | 2.92 |
| H ₂ SO ₄ | | 0.004 | 0.0041 | 0.0042 | 0.0040 | 0.0042 |
| pH | | 2.14 | 2.03 | 1.81 | 1.66 | 1.52 |
| H ₃ PO ₄ | | 0.0075 | 0.0041 | 0.0038 | 0.0031 | 0.0025 |
| pH | | 2.79 | 2.24 | 2.08 | 1.95 | 1.88 |
| HCl | | 0.0028 | 0.0021 | 0.0021 | 0.0020 | 0.0021 |
| pH | | 1.89 | 1.88 | 1.77 | 1.54 | 1.38 |

From Table (1), exhibits the maximum absorptions intensity of the colored product produced when no acid used.

Effect of ferric chloride amount: Effect of (0.25-2.0) ml of (5×10⁻³) M ferric chloride has been

studied against 30-200 µg of HAN /20 ml and the determination coefficient of a measured absorbance has been evaluated. Table (2) shows that 1.5 ml of oxidant agent solution gave the best result.

Table 2: Effect of oxidize agent amount.

| ml of FeCl ₃ (5×10 ⁻³) M | Absorbance/µg of HAN | | | | | B | R ² |
|--|----------------------|-------|-------|-------|-------|-------|----------------|
| | 30 | 50 | 100 | 150 | 200 | | |
| 0.25 | 0.095 | 0.121 | 0.223 | 0.235 | 0.280 | 0.019 | 0.9965 |
| 0.5 | 0.096 | 0.137 | 0.254 | 0.349 | 0.438 | 0.022 | 0.9969 |
| 1.0 | 0.105 | 0.170 | 0.285 | 0.386 | 0.485 | 0.043 | 0.9952 |
| 1.5 | 0.110 | 0.174 | 0.307 | 0.418 | 0.533 | 0.061 | 0.9969 |
| 2.0 | 0.105 | 0.172 | 0.299 | 0.399 | 0.512 | 0.070 | 0.9953 |

Selection of reagent and its amount

Effect of (0.25-2.5) ml of (1×10⁻²) M 2,2'-bipyridyl has been studied against 30-200 µg of HAN /20

ml and the determination coefficient of a measured absorbance has been evaluated. Table (3) shows that 1.5 ml of reagent solution gave the best result.

Table 3: Effect of 2,2'-bipyridyl amount.

| ml of 2,2'-bipyridyl (1×10 ⁻²) M | Absorbance/µg of HAN | | | | | B | R ² |
|---|----------------------|-------|-------|-------|-------|-------|----------------|
| | 30 | 50 | 100 | 150 | 200 | | |
| 0.25 | 0.058 | 0.07 | 0.092 | 0.114 | 0.133 | 0.046 | 0.9970 |
| 0.5 | 0.109 | 0.139 | 0.206 | 0.261 | 0.333 | 0.050 | 0.9982 |
| 1.0 | 0.115 | 0.176 | 0.306 | 0.421 | 0.514 | 0.058 | 0.9985 |
| 1.5 | 0.119 | 0.180 | 0.316 | 0.457 | 0.574 | 0.061 | 0.9986 |
| 2.0 | 0.106 | 0.163 | 0.302 | 0.443 | 0.554 | 0.070 | 0.9979 |
| 2.5 | 0.103 | 0.160 | 0.301 | 0.441 | 0.548 | 0.078 | 0.9971 |

Study the order of addition

Different arrangements of Drug (D), Oxidant (OX), Reagent (R), addition has been checked for

prediction the best absorbance value. Table (4) shows that the final order D+OX+R gives the best results.

Table 4: Study the order of addition.

| Order of addition | Absorbance |
|-------------------|------------|
| D+OX+R | 0.315 |
| D+R+OX | 0.303 |
| OX+D+R | 0.309 |

Study the presence of surfactant

In order to study the effect of surfactants on absorption intensity, 1ml of the anionic surfactant [sodium dodecyl sulphate (SDS)], the cationic surfactant [cetylpyridinium chloride (CPC)],

[cetyltrimethylammonium bromide (CTAB)] surfactants with the following order of (I. HAN (D)+ surfactant (S) + FeCl₃(OX)+ 2,2'-bipyridyl (R), II. D + OX +S + R, and III. D + OX + R + S). Table (5) show the result.

Table 5: Effect of surfactants.

| Surfactant solution (1×10 ⁻³ M) | Absorbance/order of addition | | |
|--|------------------------------|--------|--------|
| | I | II | III |
| SDS | Turbid | Turbid | Turbid |
| CTAB | 0.307 | 0.303 | 0.308 |
| CPC | 0.292 | 0.287 | 0.291 |

From Table (5), there is no enhancement in absorbance value in which the absorbance without surfactant is 0.316), therefore the reaction is followed without addition of surfactant.

Effect of temperature

Table 6: Effect of temp.

| Temp. | R.T(19°C) | 25 | 35 | 40 | 45 | 50 |
|------------|-----------|-------|-------|-------|-------|-------|
| Absorbance | 0.134 | 0.210 | 0.319 | 0.360 | 0.362 | 0.364 |

Time of heating

Table 7: Effect of time of oxidation.

| Temp. | 1 | 3 | 5 | 10 | 12 | 15 |
|------------|-------|-------|-------|-------|-------|-------|
| Absorbance | 0.156 | 0.240 | 0.266 | 0.362 | 0.368 | 0.368 |

Stability of reaction

The Stability of the formed complex against time has been followed using 100 µg.ml⁻¹ of HAN.

Table 8: Stability of reaction.

| Time(min) | Absorbance 100 µg of HAN/20 ml at 40°C |
|-------------|--|
| Immediately | 0.368 |
| 5 | 0.368 |
| 10 | 0.368 |
| 15 | 0.369 |
| 20 | 0.370 |
| 25 | 0.371 |
| 30 | 0.372 |
| 35 | 0.373 |
| 40 | 0.374 |
| 50 | 0.375 |
| 60 | 0.376 |
| 80 | 0.379 |
| 90 | 0.380 |
| 1 day | 0.442 |
| 5 days | 0.530 |

Table (8) indicates that the colored product is stable at least for 90 minutes in 40°C.

Absorption Spectrum

Under the optimum reaction conditions, the absorption spectrum of the formed colored product vs.blank (Fig.4) shows that wavelength of

maximum absorption intensity is 523 nm.this wavelength has been used in subsequent investigations.




Fig.4: Absorption spectrum of 100µg/20 ml of HAN measured (A) sample vs. blank (B) sample vs. distilled water and (C) blank vs. distilled water

Procedure followed in calibration graph:

The following reagents has been added in the following order:(0.05-2) ml of (100 ppm) HAN, 1 ml of (5×10^{-3} M) ferric Chloride, 1 ml of (1×10^{-2} M) 2,2'-bipyridyle, heat at 40°C and the volumes were completed to 20 ml finally measured at 523 nm. (Fig.5)

2M)2,2'-bipyridyle, heat at 40°C and the volumes were completed to 20 ml finally measured at 523 nm. (Fig.5)




Fig.5: Calibration graph of Naproxen

A linear calibration graph is obtained over the range 0.25-10 µg of Nap / ml (0.05-20 µg/20 ml) with a molar absorptivity $6.976 \times 10^4 \text{ l.mol}^{-1}.\text{cm}^{-1}$ and Sandell's index for sensitivity is $0.0309 \text{ µg.cm}^{-2}$.

Accuracy and precision: To check the accuracy and precision of the calibration graph, Nap is determined at three different concentrations; the results are shown in Table (7), which indicates good accuracy and precision.

Table 7: Accuracy and precision.

| Amount Nap taken µg/20 ml | Relative standard deviation %* | Relative error %* |
|---------------------------|--------------------------------|-------------------|
| 50 | ±0.35 | 0.15 |
| 100 | ±0.12 | 0.13 |
| 150 | ±0.10 | -0.1 |

*Average of five determinations.

Reaction ratio between naproxen and iron (III) ion

The composition of the intense orange dye has been established using Job's method and mole –

ratio method [29] fig. 6. The results show that both methods confirm the presence of 2 iron to 1 naproxen with the expected structure as in fig. 2.




Fig.6: Mole ratio method of HAN - iron (III) ion reaction

Stability constant $7.3 \times 10^{12} \text{ mol}^{-2}$. The results of estimation are given in Table (8).
 The conditional stability constant of the formed dye in aqueous solution is estimated and found to be

Table 8: Stability constant.

| ml of HAN (2×10^{-3} M) | Absorbance | | | K $\text{L}^3 \cdot \text{mol}^{-3}$ (|
|-----------------------------------|------------|------------|----------------|--|
| | A_s^* | A_m^{**} | α^{***} | |
| 0.5 | 0.245 | 0.321 | 0.310 | 2.21×10^{13} |
| 0.7 | 0.343 | 0.443 | 0.291 | 4.06×10^{13} |
| 0.1 | 0.454 | 0.558 | 0.229 | 8.08×10^{13} |

*Absorbance of the same amount of sample and reagent (1 sample:1 reagent)

**Absorbance of a maximum amount of reagent (1 sample:10 reagent)

*** Ratio of dissociation ($\alpha = A_m - A_s / A_s$)

Effect of organic solvents acid but water is still being the choice because of its availability and low cost.
 The spectrophotometric characteristic of the colored product is more detectable using acetic




Fig.7: Effect of solvents A: Ethanol B: Methanol C: Acetone D: Water E: Acetone F: Propanol

Effect of interferences μg of HAN in the presence of 100, 300, 500, 1000 μg of foreign compounds using the recommended procedure. The result is shown in Table (9).
 In order to realize the analytical application of this method, effect of foreign compounds have been studied by carrying out the determination of 100

Table 9: Effect of interferences.

| Interferences | Recovery / μg of Interferences | | | |
|---------------|---|-------|-------|-------|
| | 100 | 300 | 500 | 1000 |
| Starch | 99.2 | 99.3 | 100.1 | 99.2 |
| Glucose | 97.8 | 98.1 | 99.2 | 100.3 |
| Lactose | 96.4 | 96.8 | 96.9 | 97.0 |
| Fructose | 100.2 | 100.0 | 99.5 | 97.3 |

Application of the method

To test the applicability of the present method, it has been applied to the determination of Nap in

pharmaceutical preparations. The results are listed in Table (11) indicating a good applicability of the method.

Table 10: application of the method.

| Amount of Nap /20 ml | Recovery* (%) of Nap | | |
|----------------------|---|--------------------------------------|---|
| | Naproxen (tablet 500 mg) - Inaprolfort, Bilim, Turkey | Naproxen (tablet 500 mg)-S.D.I, Iraq | Naprox (tablet 500mg) -Medical Bahri Company, Damascus -Syria |
| 50 | 99.9 | 98.8 | 96.4 |
| 100 | 100.0 | 98.4 | 99.5 |
| 150 | 100.2 | 99.1 | 99.2 |

*Average of three determinations.

t-test

Both the present method and British Pharmacopeia method [30] has been applied at the same time to t-test calculation [31] and the value compared with statistical tables for four degree of freedom at 95%

validation level. The result in Table (11) show that there is no a real difference between the two methods.

Table 11: T-test.

| Drug | Recovery * % | | t-exp |
|---|----------------|-----------------------------|-------|
| | Present method | British Pharmacopeia method | |
| Naproxen (tablet 500 mg)-Inaprolfort, Bilim, Turkey | 100.0 | 99.9 | 0.230 |
| Naprox (tablet 500mg) -Medical Bahri Company, Damascus -Syria | 98.3 | 97.4 | 0.838 |

ACKNOWLEDGMENT

The authors are grateful to the University of Mosul, College of science, and to the department of chemistry for providing facilities to carry out this work.

REFERENCES

- Zheng, W., Fan, W., Zhang, S., Jiao, P., Shang, Y., Cui, L., ... Mahesutihan, M. (2019). Naproxen exhibits broad anti-influenza virus activity in mice by impeding viral Nucleoprotein nuclear export. *Cell Reports*, 27(6), 1875-1885.e5. doi: 10.1016/j.celrep.2019.04.053.
- Dilly, S., Fotso Fotso, A., Lejal, N., Zedda, G., Chebbo, M., Rahman, F., ... Slama-Schwok, A. (2018). From Naproxen repurposing to Naproxen analogues and their antiviral activity against influenza A virus. *Journal of Medicinal Chemistry*, 61(16), 7202-7217. doi: 10.1021/acs.jmedchem.8b00557.
- Lejal, N., Tarus, B., Bouguyon, E., Chenavas, S., Bertho, N., Delmas, B., ... Slama-Schwok, A. (2013). Structure-based discovery of the novel antiviral properties of Naproxen against the Nucleoprotein of influenza A virus. *Antimicrobial Agents and Chemotherapy*, 57(5), 2231-2242. doi:10.1128/aac.02335-12.
- Terrier, O., Dilly, S., Pizzorno, A., Henri, J., Berenbaum, F., Lina, B., Schwok, A. S. (2020). Broad-spectrum antiviral activity of naproxen: from Influenza A to SARS-CoV-2 Coronavirus. bioRxiv preprint, doi:10.1101/2020.04.30.069922.
- Wishart, D. S., Knox, C., Guo, A. C., Shrivastava, S., Hassanali, M., Stothard, P., Woolsey, J. (2006). DrugBank: a comprehensive resource for in silico drug discovery and exploration. *Nucleic Acids Research*, 34(Database issue), D668-72.
- ., Takagi, T., Ramachandran, C., Bermejo, M. (2006). Yamashita, S., Yu, L. X., & Amidon, G. L. A provisional Biopharmaceutical classification of the top 200 oral drug products in the United States, Great Britain, Spain, and Japan. *Molecular* .631-643 , (6) *Pharmaceutics*, 3 doi:10.1021/mp0600182.
- Mahmood, H. S., & Al-Sarraj, T. Z. (2019). A Creative Indirect Spectrophotometric Determination of Naproxen. *Rafidain Journal of Science*, 28(1), 51-60.
- Mahmood, H. S. (2020). Two novel spectrophotometric methods for determination of naproxen via a modulation to hydroxy analog. *Current Applied Science and Technology*, 20(2), 295-309. doi:10.14456/CAST.2020.17.
- Soltani, N., Tavakkoli, N., Mosavimanesh, Z. S., & Davar, F. (2018). Electrochemical determination of naproxen in the presence of acetaminophen using a carbon paste electrode modified with activated carbon nanoparticles. *Comptes Rendus Chimie*, 21(1), 54-60. doi: 10.1016/j.crci.2017.11.007.
- Lenik, J., Dumkiewicz, R., Wardak, C., & Marczevska, B. (2002). Naproxen ion-selective electrode and its application to pharmaceutical

- analysis. *Acta Poloniae Pharmaceutica*, 59(3), 171–176.
11. Li, Y., & Lu, J. (2006). Flow injection chemiluminescence determination of naproxen based on KMnO_4 – Na_2SO_3 reaction in neutral aqueous medium. *Analytica Chimica Acta*, 577(1), 107–110. doi: 10.1016/j.aca.2006.06.022.
 12. Alhazmi, H. A., & Al Bratty, M. (2017). Conductometric determination of naproxen in bulk and pharmaceutical dosage form. *European Journal of Chemistry*, 8(4), 339–343. doi:10.5155/eurjchem.8.4.339-343.1614.
 13. Wahbi, A. A. M., Mabrouk, M. M., Moneeb, M. S., & Kamal, A. H. (2009). Simultaneous determination of the two non-steroidal anti-inflammatory drugs; diflunisal and naproxen in their tablets by chemometric spectrophotometry and HPLC. *Pakistan journal of pharmaceutical sciences*, 22(1).
 14. Tashtoush, B. M., & Al-Taani, B. M. (2003). HPLC determination of naproxen in plasma. *Die Pharmazie*, 58(9), 614–615.
 15. Muneer, S., Muhammad, I. N., Asad Abrar, M., Munir, I., Kaukab, I., Sagheer, A., ... Sultana, K. (2017). High performance liquid chromatographic determination of Naproxen in prepared pharmaceutical dosage form and human plasma and its application to pharmacokinetic study. *Journal of Chromatography & Separation Techniques*, 08(03). doi:10.4172/2157-7064.1000369.
 16. Nijhu, R. S., Jhanker, Y. M., & Sutradhar, K. B. (2011). Development of an assay method for simultaneous determination of Ciprofloxacin and Naproxen by UV spectrophotometric method. *Stamford Journal of Pharmaceutical Sciences*, 4(1), 84–90.
 17. Veeragoni, A. K., Sindgi, V. M., & Satla, S. R. (2016). Bioanalytical validated LC-MS method for determination of naproxen in human plasma. *International J. for Modern Trends in Sci. and Technol*, 2(9), 96–99.
 18. Bag, P. P., & Sahoo, P. (2019). Designing metal-organic frameworks based Photocatalyst for specific photocatalytic reactions: A crystal engineering approach. *Environmental Chemistry for a Sustainable World*, 141–186. doi:10.1007/978-3-030-17638-9_6.
 19. Neurohr, C., Marchivie, M., Lecomte, S., Cartigny, Y., Couvrat, N., Sanselme, M., & Subra-Paternault, P. (2015). Naproxen–nicotinamide Cocrystals: Racemic and conglomerate structures generated by CO_2 Antisolvent crystallization. *Crystal Growth & Design*, 15(9), 4616–4626. doi: 10.1021/acs.cgd.5b00876.
 20. Sarraguça, M. C., Ribeiro, P. R., Dos Santos, A. O., & Lopes, J. A. (2015). Batch statistical process monitoring approach to a cocrystallization process. *Journal of pharmaceutical sciences*, 104(12), 4099–4108.
 21. Nechipadappu, S. K., & Trivedi, D. R. (2017). Structural and physicochemical characterization of pyridine derivative salts of anti-inflammatory drugs. *Journal of Molecular Structure*, 1141, 64–74. doi: 10.1016/j.molstruc.2017.03.086
 22. Sloka, S. N., Gurupadaya, B. M., & Kumar, C. A. (2011). Simultaneous spectrophotometric determination of Naproxen and Pantoprazole in pharmaceutical dosage form. *Journal of Applied Chemical Research*, 17, 65–74.
 23. Nijhu, R. S., Jhanker, Y. M., & Sutradhar, K. B. (2011). Development of an assay method for simultaneous determination of Ciprofloxacin and Naproxen by UV spectrophotometric method. *Stamford Journal of Pharmaceutical Sciences*, 4(1), 84–90.
 24. Maheshwari, R. K., Lakkadwala, S., Vyas, R., & Ghode, P. (2010). Spectrophotometric determination of naproxen tablets using niacinamide as hydrotropic solubilizing additive. *J. Current Pharmaceutical Research*, 4, 11–14.
 25. Jain, N. A., Lohiya, R. T., & Umekar, M. J. (2011). Spectrophotometric determination of naproxen and esomeprazole in a laboratory mixture by Simultaneous equation, absorption correction, absorption ratio and area under curve methods. *Intern. J. Pharm. Sci. Res*, 2(5), 130–134.
 26. Connelly, P. R., Vuong, T. M., & Murcko, M. A. (2011). Getting physical to fix Pharma. *Nature Chemistry*, 3(9), 692–695. doi:10.1038/nchem.1121.
 27. Senior, K. L. (2009). Isolation of Naproxen.
 28. Al-Hamdany, F. K. (2009). Synthesis of some (s)-2-(6'-methoxy-2'-naphthyl) propanoic acid derivatives (Naproxen) (Doctoral dissertation, Ph. D. thesis, university of Mosul).
 29. Meyer, A. S., & Ayres, G. H. (1957). The mole ratio method for Spectrophotometric determination of complexes in Solution I. *Journal of the American Chemical Society*, 79(1), 49–53. doi:10.1021/ja01558a011.
 30. Church, H. J. (2013). The chemical processes of the British pharmacopeia. The classics.
 31. Christian, G. D. (2011). Analytical Chemistry (6th ed.). Wiley.